Skip to main content

Research Repository

Advanced Search

Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer

Lashen, Ayat G.; Toss, Michael S.; Rutland, Catrin S.; Green, Andrew R.; Mongan, Nigel P.; Rakha, Emad

Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer Thumbnail


Authors

Ayat G. Lashen

Michael S. Toss

CATRIN RUTLAND CATRIN.RUTLAND@NOTTINGHAM.AC.UK
Professor of Molecular Medicine

NIGEL MONGAN nigel.mongan@nottingham.ac.uk
Associate Pro-Vice Chancellorglobal Engagement

EMAD RAKHA Emad.Rakha@nottingham.ac.uk
Professor of Breast Cancer Pathology



Abstract

Introduction: Minichromosome maintenance complex component 7 (MCM7) plays an essential role in proliferation and DNA replication of cancer cells. However, the expression and prognostic significance of MCM7 in breast cancer (BC) remain to be defined. In this study, we aimed to evaluate the role of MCM7 in BC. Methods: We conducted immunohistochemistry staining of MCM7 in 1156 operable early-stage BC samples and assessed MCM7 at the transcriptomic levels using publicly available cohorts (n=13,430). MCM7 expression was evaluated and correlated with clinicopathological parameters including Ki67 labelling index and patient outcome. Results: At the transcriptomic level, there was a significant association between high MCM7 mRNA levels and shorter patient survival in the whole cohort and in luminal BC class but not in the basel-like molecular subtype. High MCM7 protein expression was detected in 43% of patients and was significantly associated with parameters characteristic of aggressive tumour behaviour. MCM7 was independently associated with shorter survival, particularly in estrogen receptor-positive (luminal) BC. MCM7 stratified luminal tumours with aggressive clinicopathological features into distinct prognostic groups. In endocrine therapy treated BC patients, high MCM7 was associated with poor outcome but such association disappeared with administration of adjuvant chemotherapy. Patients with high expression of Ki67 and MCM7 showed worst survival while patients with double low expression BC showed the best outcome compared with single expression groups. Conclusion: The current findings indicate that MCM7 expression has a prognostic value in BC and can be used to identify luminal BC patients who can benefit from adjuvant chemotherapy.

Citation

Lashen, A. G., Toss, M. S., Rutland, C. S., Green, A. R., Mongan, N. P., & Rakha, E. (2024). Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer. Pathobiology, https://doi.org/10.1159/000540790

Journal Article Type Article
Acceptance Date Aug 5, 2024
Online Publication Date Aug 27, 2024
Publication Date Aug 27, 2024
Deposit Date Aug 16, 2024
Publicly Available Date Sep 17, 2024
Journal Pathobiology
Print ISSN 1015-2008
Electronic ISSN 1423-0291
Publisher Karger Publishers
Peer Reviewed Peer Reviewed
DOI https://doi.org/10.1159/000540790
Keywords Breast cancer; MCM7; endocrine; prognosis; molecular classes
Public URL https://nottingham-repository.worktribe.com/output/38382936
Publisher URL https://karger.com/pat/article/doi/10.1159/000540790/912413/Prognostic-and-Clinical-Significance-of-the

Files






You might also like



Downloadable Citations